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Which Risk Factors Matter 
to Whom?
DOI: 10.1371/journal.pmed.0010029
There is a much-quoted saying, 
attributed to the epidemiologist Geoffrey 
Rose:  “A large number of people exposed 
to a small risk may generate many more 
cases than a small number exposed to 
a very high risk.” This is true for many 
individual risk factors such as salt intake 
(linked to high blood pressure and 
cardiovascular disease) and speeding 
on the highway (linked to injuries and 
accidents). Does it apply to many other 
global health risks? The study by Anthony 
Rodgers and colleagues suggests that it 
does. 
To develop effective health policies, 
one must understand the existing 
health risks and disease burdens. 
On a worldwide scale, this is a tough 
challenge. The Global Burden of Disease 
Database, maintained by the World 
Health Organization (WHO), collects data 
from countries around the world on risk 
factors such as tobacco, malnutrition, 
childhood abuse, unsafe sex, childbirth, 
and cholesterol levels, as well as on 
disease burdens, for example depression, 
blindness, and diarrhea. A large group 
of scientists from all over the world 
has developed a framework to analyze 
these data. To compare different risks 
or burdens, they calculate disability-
adjusted life-years, or DALYs—the 
number of healthy life years lost because 
of a particular disease or risk factor.
Rodgers and colleagues used data 
from the WHO database for 26 risk factors 
and from 14 epidemiological subregions 
of the world to calculate the proportion 
of risk-factor-attributable disease burden 
in different population subgroups 
deﬁ  ned by age, sex, and exposure level. 
For being underweight in childhood, 
for example—the leading risk factor for 
global loss of healthy life—they found 
that only 35% of the disease burden 
occurred in severely underweight 
children, the rest occurred in those only 
moderately underweight. The relative 
risks for the moderately underweight are 
much lower, but the number of children 
in that category is so large that the total 
attributable burden amounted to almost 
two-thirds of the total global burden of 
disease for that risk factor. 
The analysis conﬁ  rms—and extends 
to a global level—previous research 
showing that many major health risks are 
important across the range of exposure 
levels, not just among individuals 
exposed to high levels of risk. It also 
points to risk factors that are particularly 
prevalent among speciﬁ  c populations 
and age groups, and for which highly 
targeted interventions could be effective. 
Despite numerous caveats and 
limitations of studies like this one, such 
analyses are essential aids in guiding the 
distribution of limited funds to lower the 
burden of life years lost to premature 
death and disability. 
Rodgers A, Ezzati M, Vander Hoorn S, 
Lopez AD, Lin RB, et al. (2004) Distribution 
of major health risks: Findings from the 
Global Burden of Disease study. DOI: 
10.1371/journal.pmed.0010027
DOI: 10.1371/journal.pmed.0010029.g001
Tobacco is a major player in the global 
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Getting the Fluid Balance Right 
in Malaria
DOI: 10.1371/journal.pmed.0010024
Acidosis is a major cause of death 
in patients with malaria, although 
what causes acidosis is still unclear. 
One possibility is that hypovolemia 
contributes to the problem, and that 
rehydration therapy could be of beneﬁ  t. 
Now, Sanjeev Krishna and colleagues 
have shown that in children with severe 
malaria dehydration is not severe and 
is not correlated with other measures 
of disease severity.  “The optimum 
resuscitation approach in severe 
childhood malaria remains to be deﬁ  ned,” 
says Nick White (Mahidol University, 
Thailand), the academic editor of the 
paper.  “The relative advantages of blood, 
colloids, and crystalloids need to be 
characterized.”
Every year around 200 million 
people worldwide contract malaria, 
of whom over a million die. The vast 
majority of those who die are children 
under ﬁ  ve years, mostly in Africa, 
since young children have had little 
chance to acquire any immunity. Fluid 
resuscitation is generally considered 
to be a cornerstone of treatment—but 
how much ﬂ  uid should be given? Some 
researchers believe that surrogate signs 
of ﬂ  uid depletion—such as tachycardia, 
reduced capillary reﬁ  ll time, and reduced 
urine excretion—suggest that there 
is substantial volume depletion. The 
reason that the amount of ﬂ  uid given 
matters so much is that giving too much, 
especially of hypotonic solutions, can 
lead to electrolyte imbalance, especially 
hyponatremia and hypokalemia. 
Research efforts have been hampered 
by not having an easy way to assess in 
patients the ﬂ  uid depletion in different 
compartments of the body, i.e., total 
body water and extracellular and 
intracellular water volume. Krishna and 
colleagues used heavy-water distribution 
to calculate the total body water and 
bromide distribution to determine the 
extracellular volume in 19 children with 
moderately severe malaria and 16 with 
severe malaria in Gabon. By subtracting 
extracellular volume from total body 
water, they were able to calculate 
intracellular volume for each child. They 
also used a less invasive and more rapid 
method of determining water volumes 
based on using bioelectrical impedance 
to calculate the volume.
None of the children were severely 
dehydrated (deﬁ  ned as more than 100 
ml/kg depletion), and only three of the 
children with severe anemia had ﬂ  uid 
depletion, which was moderate (60–90 
ml/kg depletion).  “This challenges the 
DOI: 10.1371/journal.pmed.0010024.g001
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T Cells Cause Lung Damage in Emphysema
DOI: 10.1371/journal.pmed.0010025
T lymphocytes may have an important role in the pathogenesis 
of smoking-related emphysema, according to a new study by 
researchers from Houston, Texas, United States.  “We now know 
that T cells are not only present in chronic obstructive pulmonary 
disease [COPD], but are harmful,” comments Steven Shapiro from 
Brigham and Women’s Hospital, Harvard Medical School, who was 
not involved in the study.  “We also now have a pathway that could 
be interrupted to prevent lung destruction in COPD.”
Farrah Kheradmand and colleagues took lung samples from 28 
ex-smokers who had been admitted to hospital for lung resection: 
18 patients had moderate to severe COPD as well as evidence of 
emphysema, and ten patients had none. The researchers isolated 
lung lymphocytes from the samples and used two-color ﬂ  ow 
cytometry to phenotypically characterize the cells. They found that 
lymphocytes taken from patients with emphysema expressed more 
CCR5 and CXCR3 receptors, which are associated with a particular 
type of T cell called T helper 1 (Th1), than did those from control 
individuals. By contrast, expression of CCR4 receptors, which are 
found on T helper 2 (Th2) cells, was very low in both control and 
emphysema groups. 
In a separate experiment, Kheradmand’s team showed that lung 
lymphocytes taken from patients with emphysema secreted more 
of three other proteins—interferon gamma, monokine induced 
DOI: 10.1371/journal.pbio.0010025.g001
CT image of the lung of subjects with end-stage emphysema next to a 
photomicrograph of their resected lung stained with H&E
view that dehydration is a major contributor to the pathology of 
this frequently lethal disease,” says White.
So based on these data, obtained from a carefully studied, 
albeit small group of children, what should people who treat 
children with malaria do? The authors’ ﬁ  rst recommendation is that 
clinicians should think again about how vigorously they rehydrate 
children, and if they have access to ways of assessing ﬂ  uid volume 
more precisely, they should do so (not a trivial undertaking in 
many hospitals where these children are treated). And certainly the 
methods used by Krishna and colleagues should undergo wider 
testing in larger groups of children to conﬁ  rm their usefulness. Until 
the worldwide efforts to prevent malaria come to fruition, reﬁ  ning 
the management of infected children will remain a cornerstone of 
the efforts against this devastating disease.
Planche T, Onanga M, Schwenk A, Dzeing A, Borrmann S, et al. 
(2004) Assessment of volume depletion in children with malaria. DOI: 
10.1371/journal.pmed.001001
Different HIV Drugs Cause Different 
Lipid Proﬁ  les
DOI: 10.1371/journal.pmed.0010030
Nevirapine and efavirenz are the most commonly 
prescribed of the class of antiretroviral drugs called 
non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
Efavirenz has the advantage of once-daily dosing. In a 
recent study called the 2NN study (Lancet 363: 1253–1263), 
it appeared to be only marginally superior to nevirapine in 
terms of clinical success and virological suppression. Van 
Leth and colleagues have now shown that while nevirapine 
and efavirenz both raise high-density lipoprotein (HDL) 
cholesterol (the “good” type of cholesterol), the overall lipid 
proﬁ  le is better with nevirapine than with efavirenz.
“These data suggest that nevirapine may be preferable 
to efavirenz in HIV-infected adults with other cardiovascular 
risk factors,” says the study’s academic editor, Andrew Carr 
of St. Vincent’s Hospital in Darlinghurst, Australia.  “However, 
perceived cardiovascular risk is only one factor that would 
affect the choice between these two drugs.”
Van Leth and colleagues prospectively analyzed the 
lipids of patients enrolled in the 2NN study, a randomized, 
open-label efﬁ  cacy study that included adults with HIV 
who had never been on antiretroviral drugs. All patients 
were given stavudine and lamivudine and were then 
randomized into three treatment groups: nevirapine, 
efavirenz, or both. 
For the lipid analysis, which was preplanned, the 
researchers included only the nevirapine and efavirenz 
groups (417 and 289 patients, respectively). This was 
because the 2NN study showed that simultaneous use 
of nevirapine and efavirenz should be avoided—the 
combination is associated with increased toxicity without 
increased efﬁ  cacy. The increase in HDL cholesterol was 
signiﬁ  cantly higher with nevirapine than with efavirenz. 
There was a decrease in the ratio of total cholesterol to 
HDL cholesterol with nevirapine and an increase with 
efavirenz.
The study does not prove, however, that the rise in 
HDL cholesterol seen with NNRTIs (especially nevirapine) 
actually leads to a reduction in coronary heart disease.  
“There are no vascular functional data,” says Carr,  “or 
clinical vascular endpoint data that conﬁ  rm that the 
statistically signiﬁ  cant lipid differences observed are 
clinically signiﬁ  cant.”
The study was funded by Boehringer Ingelheim, the 
manufacturer of nevirapine. The authors clearly state that 
the company had “a nonbinding input on issues of study 
design and analyses” but it had “no inﬂ  uence on reporting 
of the data or the decision to publish.”
Despite its limitations, van Leth and colleagues’ study 
“moves clinicians and patients away from ‘one-size-ﬁ  ts-
all’ antiretroviral therapy,” says Carr.  “It takes us further 
along the path of choice of antiretroviral therapy being 
individualized according to other patient co-morbidities 
and risk factors, as well as therapy simplicity and side 
effects.”
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, et al. 
(2004) Nevirapine and efavirenz elicit different changes in 
lipid proﬁ  les in antiretroviral-therapy-naive patients infected 
with HIV-1. DOI: 10.1371/journal.pmed.0010019
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Most patients with celiac disease can 
eliminate their symptoms—at a price: 
life-long adherence to a gluten-free diet. 
This means no wheat, rye, barley, and, 
until recently, no oats. Then some recent 
studies suggested that oats did not cause 
the intestinal inﬂ  ammation characteristic 
of the disease, and thus oats are now 
often included in the celiac disease diet. 
This is good news for patients coping 
with severe restrictions on what they can 
and must not eat, but a study by Ludvig 
Sollid and colleagues in this issue of PLoS 
Medicine suggests that oats are not safe 
in all cases. 
Like other chronic inﬂ  ammatory 
diseases, celiac disease is caused by a 
complex interplay between genetic and 
environmental factors, but it is better 
understood than most. Long believed 
to be a relatively rare disorder, it is now 
thought to affect about one in 250 
people worldwide. Clinical symptoms are 
present in less than half of patients and 
vary considerably. Genetically, almost all 
patients have one of two predisposing 
HLA molecules, which 
determine the context 
in which their immune 
system encounters 
foreign antigens, 
including gluten 
proteins found in wheat 
and other cereals. In 
individuals with celiac 
disease, the immune 
system mounts an 
abnormal response 
to gluten, which is 
characterized by gluten-
reactive intestinal T cells 
and by inﬂ  ammation and 
compromised function of 
the small intestine. 
Ludvig Sollid and colleagues applied 
the current understanding of celiac 
disease and a range of molecular 
pathology tools to studying the response 
to oats of nine patients with celiac 
disease. The nine patients were not a 
random sample: all of them had been 
eating oats, and four of them had shown 
clinical symptoms after oats ingestion. 
The goal of the study was to characterize 
the intestinal T cell response to oats 
in these patients, and to relate it to 
clinical symptoms and intestinal biopsy 
results. All patients were on a gluten-
free diet and ate oats that were free of 
contamination by other cereals. 
Three of the four patients who had 
reported problems after eating oats 
showed intestinal inﬂ  ammation typical of 
celiac disease, and Sollid and colleagues 
studied intestinal T cells from these three 
patients. Two of the ﬁ  ve patients who 
seemed to tolerate oats also had oats-
reactive intestinal T cells. Functional study 
of these T cells showed that they were 
restricted to celiac-disease-associated 
HLA molecules and that they recognized 
two peptides derived from oat avenin 
that are very similar to peptides of gluten. 
Taken together, the ﬁ  ndings show that 
intolerance to oats exists at least in some 
patients with celiac disease, and that 
those patients have the same molecular 
reaction to oats that other patients 
have to wheat, barley, or rye. However, 
identical reactions were also seen in 
two of the patients who were clinically 
tolerant to oats. The authors suggest 
that these reactions could develop into 
symptomatic disease after some time 
delay, but there is no proof that the 
presence of oats-reactive T cells is an 
indicator of future symptoms or even of 
enhanced susceptibility to clinical oats 
intolerance. 
Oats are not safe for all patients with 
celiac disease, but future studies are 
needed to determine the frequency of 
oats intolerance. 
Arentz-Hansen H, Fleckenstein B, Molberg 
Ø, Scott H, Koning F, et al. (2004) The 
molecular basis for oat intolerance in celiac 
disease patients. DOI: 10.1371/journal.
pmed.0010001
DOI: 10.1371/journal.pbio.0010023.g001
The celiac diet excludes many cereal products 
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by interferon (MIG), and interferon-inducible protein 10 (IP-10)—than control patients. 
MIG and IP-10 are known to be produced by injured epithelial cells and are ligands 
for CXCR3 receptors, which are expressed by Th1 cells. Importantly, the researchers 
were also able to show that isolated peripheral lung macrophages secreted  matrix 
metalloproteinase-12 (MMP12), an enzyme that degrades elastin—a protein important 
for lung elasticity—in the lungs, in response to IP-10 and MIG. Together these ﬁ  ndings, 
say the authors, indicate that Th1 cells, but not Th2 cells, are required for producing the 
elastin-destroying lung environment of emphysema.
The researchers now intend to investigate the antigens that drive the Th1-based 
inﬂ  ammation that underlies emphysema. “Ultimately, we seek to understand the 
biochemistry of tobacco smoke that triggers inﬂ  ammation in the ﬁ  rst place, and 
whether such insight might explain other environmentally triggered lung diseases,” 
explains Kheradmand. “To understand such detailed immune mechanisms, we really 
need an improved experimental model of disease, and this we are currently working on.”
Grumelli S, Corry DB, Song LZ, Song L, Green L, et al. (2004) An immune basis for lung 
parenchymal destruction in chronic obstructive pulmonary disease and emphysema. DOI: 
10.1371/journal.pmed.0010008
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Oats Intolerance in Celiac Disease
DOI: 10.1371/journal.pmed.0010023